| Year |
Citation |
Score |
| 2021 |
Wright GM, Gimbrone NT, Sarcar B, Percy TR, Gordián ER, Kinose F, Sumi NJ, Rix U, Cress WD. CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines. Plos One. 16: e0252927. PMID 34138895 DOI: 10.1371/journal.pone.0252927 |
0.383 |
|
| 2019 |
Xie M, Zheng H, Madan-Lala R, Dai W, Gimbrone NT, Chen Z, Kinose F, Blackstone SA, Smalley KSM, Cress WD, Haura EB, Rix U, Beg AA. MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer. Cancer Research. PMID 31362929 DOI: 10.1158/0008-5472.Can-19-0698 |
0.516 |
|
| 2019 |
Gordian E, Welsh EA, Gimbrone N, Siegel EM, Shibata D, Creelan BC, Cress WD, Eschrich SA, Haura EB, Muñoz-Antonia T. Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer. Oncotarget. 10: 810-824. PMID 30783512 DOI: 10.18632/Oncotarget.26574 |
0.378 |
|
| 2019 |
Raez LE, Saravia D, Ruiz R, Sumarriva D, Munoz-Antonia T, Hunis B, Cress WD, Mas L, Izquierdo P, Kaen D, Lopes G, Antonia SJ. Clinical responses and survival in Hispanic patients with non-small cell lung cancer treated with immunotherapy compared with non-Hispanic whites. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E18109 |
0.388 |
|
| 2018 |
Pérez-Morales J, Mejías-Morales D, Rivera-Rivera S, González-Flores J, González-Loperena M, Cordero-Báez FY, Pedreira-García WM, Chardón-Colón C, Cabán-Rivera J, Cress WD, Gordian ER, Muñoz-Antonia T, Cabrera-Ríos M, Isidro A, Coppola D, et al. Hyper-phosphorylation of Rb S249 together with CDK5R2/p39 overexpression are associated with impaired cell adhesion and epithelial-to-mesenchymal transition: Implications as a potential lung cancer grading and staging biomarker. Plos One. 13: e0207483. PMID 30452490 DOI: 10.1371/Journal.Pone.0207483 |
0.41 |
|
| 2018 |
Raez LE, Munoz-Antonia T, Cress WD, Hunis B, Chiappori A, Dietrich M, Antonia SJ, Powery H, Izquierdo P, Sumarriva D. Lung cancer immunotherapy outcomes in Hispanic patients. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E18665 |
0.362 |
|
| 2017 |
Gimbrone NT, Sarcar B, Gordian ER, Rivera JI, Lopez C, Yoder SJ, Teer JK, Welsh EA, Chiaporri AA, Schabath MB, Reuther GW, Dutil J, Garcia M, Ventosilla-Villanueva R, Vera-Valdivia L, ... ... Cress WD, et al. Brief Report: Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28911955 DOI: 10.1016/J.Jtho.2017.08.019 |
0.373 |
|
| 2017 |
Teer JK, Zhang Y, Chen L, Welsh EA, Cress WD, Eschrich SA, Berglund AE. Evaluating somatic tumor mutation detection without matched normal samples. Human Genomics. 11: 22. PMID 28870239 DOI: 10.1186/S40246-017-0118-2 |
0.31 |
|
| 2017 |
Cress WD, Yu P, Wu J. Expression and alternative splicing of the cyclin-dependent kinase inhibitor-3 gene in human cancer. The International Journal of Biochemistry & Cell Biology. PMID 28504190 DOI: 10.1016/J.Biocel.2017.05.013 |
0.521 |
|
| 2017 |
Gordian E, Gimbrone N, Pannuti A, Miele L, Cress WD, Muñoz-Antonia T. Abstract 4456: Novel oncogenic function of Notch4 in Hispanic lung cancer Cancer Research. 77: 4456-4456. DOI: 10.1158/1538-7445.Am2017-4456 |
0.471 |
|
| 2016 |
Chen L, Kurtyka CA, Welsh EA, Rivera JI, Engel BE, Muñoz-Antonia T, Yoder SJ, Eschrich SA, Creelan BC, Chiappori AA, Gray JE, Ramirez JL, Rosell R, Schabath MB, Haura EB, ... ... Cress WD, et al. Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma. Oncotarget. PMID 27756884 DOI: 10.18632/Oncotarget.12672 |
0.348 |
|
| 2016 |
Jhuraney A, Woods NT, Wright G, Rix L, Kinose F, Kroeger JL, Remily-Wood E, Cress WD, Koomen JM, Brantley SG, Gray JE, Haura EB, Rix U, Monteiro AN. PAXIP1 potentiates the combination of WEE1 inhibitor AZD1775 and platinum agents in lung cancer. Molecular Cancer Therapeutics. PMID 27196765 DOI: 10.1158/1535-7163.Mct-15-0182 |
0.456 |
|
| 2016 |
Chen Z, Li JL, Lin S, Cao C, Gimbrone NT, Yang R, Fu DA, Carper MB, Haura EB, Schabath MB, Lu J, Amelio AL, Cress WD, Kaye FJ, Wu L. cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth. The Journal of Clinical Investigation. PMID 27140397 DOI: 10.1172/Jci85250 |
0.558 |
|
| 2016 |
Chen L, Engel BE, Welsh EA, Yoder SJ, Brantley SG, Chen DT, Beg AA, Cao C, Kaye FJ, Haura EB, Schabath MB, Cress WD. A sensitive NanoString-based assay to score STK11 (LKB1) pathway disruption in lung adenocarcinoma. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26917230 DOI: 10.1016/J.Jtho.2016.02.009 |
0.412 |
|
| 2016 |
Cao C, Gao R, Zhang M, Amelio AL, Fallahi M, Chen Z, Gu Y, Hu C, Welsh EA, Engel BE, Haura E, Cress WD, Wu L, Zajac-Kaye M, Kaye FJ. Abstract A22: An LKB1-CRTC1 circuit regulates glycosylated COX-2 and predicts drug response in lung cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Metca15-A22 |
0.469 |
|
| 2016 |
Fan C, Chen L, Huang Q, Shen T, Welsh EA, Teer JK, Cress WD, Wu J. Abstract 190: Mechanism ofCDKN3overexpression in cancer Cancer Research. 76: 190-190. DOI: 10.1158/1538-7445.Am2016-190 |
0.503 |
|
| 2015 |
Sosa-García B, Vázquez-Rivera V, González-Flores JN, Engel BE, Cress WD, Santiago-Cardona PG. The Retinoblastoma Tumor Suppressor Transcriptionally Represses Pak1 in Osteoblasts. Plos One. 10: e0142406. PMID 26555075 DOI: 10.1371/Journal.Pone.0142406 |
0.526 |
|
| 2015 |
Fan C, Chen L, Huang Q, Shen T, Welsh EA, Teer JK, Cai J, Cress WD, Wu J. Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma. British Journal of Cancer. PMID 26554648 DOI: 10.1038/Bjc.2015.378 |
0.456 |
|
| 2015 |
Baldelli E, Bellezza G, Haura EB, Crinó L, Cress WD, Deng J, Ludovini V, Sidoni A, Schabath MB, Puma F, Vannucci J, Siggillino A, Liotta LA, Petricoin EF, Pierobon M. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors. Oncotarget. PMID 26468985 DOI: 10.18632/Oncotarget.5941 |
0.423 |
|
| 2015 |
Cao C, Gao R, Zhang M, Amelio AL, Fallahi M, Chen Z, Gu Y, Hu C, Welsh EA, Engel BE, Haura EB, Cress WD, Wu L, Zajac-Kaye M, Kaye FJ. Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer. Journal of the National Cancer Institute. 107: 358. PMID 25465874 DOI: 10.1093/Jnci/Dju358 |
0.419 |
|
| 2014 |
Cress WD, Chiappori A, Santiago P, Muñoz-Antonia T. Lung cancer mutations and use of targeted agents in Hispanics. Reviews On Recent Clinical Trials. 9: 225-32. PMID 25626064 DOI: 10.2174/1574887110666150127103555 |
0.374 |
|
| 2014 |
Chen L, Muñoz-Antonia T, Cress WD. Trim28 contributes to EMT via regulation of E-cadherin and N-cadherin in lung cancer cell lines. Plos One. 9: e101040. PMID 24983967 DOI: 10.1371/Journal.Pone.0101040 |
0.488 |
|
| 2014 |
Kurtyka CA, Chen L, Cress WD. E2F inhibition synergizes with paclitaxel in lung cancer cell lines. Plos One. 9: e96357. PMID 24831239 DOI: 10.1371/Journal.Pone.0096357 |
0.478 |
|
| 2014 |
Donatelli SS, Zhou JM, Gilvary DL, Eksioglu EA, Chen X, Cress WD, Haura EB, Schabath MB, Coppola D, Wei S, Djeu JY. TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells. Proceedings of the National Academy of Sciences of the United States of America. 111: 4203-8. PMID 24586048 DOI: 10.1073/Pnas.1319269111 |
0.361 |
|
| 2014 |
Santiago-Cardona PG, Engel BE, González-Flores J, Cruz-Cosme R, Muñoz-Antonia T, Cress WD. Abstract C19: Molecular biology of lung cancer in Puerto Ricans Cancer Epidemiology, Biomarkers & Prevention. 23. DOI: 10.1158/1538-7755.Disp13-C19 |
0.474 |
|
| 2014 |
Kurtyka CA, Chen L, Schabath MB, Chen D, Brazelle W, Welsh EA, Berglund AE, Eschrich SA, Gray JE, Haura EB, Cress WD. Abstract 914: Development of a prognostic and predictive E2F signature in formalin-fixed, paraffin-embedded early-stage non-small cell lung cancer samples Cancer Research. 74: 914-914. DOI: 10.1158/1538-7445.Am2014-914 |
0.435 |
|
| 2014 |
Engel BE, Schabath MB, Thompson ZJ, Eschrich SA, Brantley SG, Belock AR, Berglund A, Gray JE, Beg AA, Haura EB, Cress WD. Abstract 4159: Characterization of three recurring STK11/LKB1 mutants in lung adenocarcinoma Cancer Research. 74: 4159-4159. DOI: 10.1158/1538-7445.Am2014-4159 |
0.435 |
|
| 2013 |
Kurtyka CA, Chen D, Chen L, Brazelle W, Welsh EA, Berglund AE, Eschrich SA, Schabath MB, Haura EB, Cress WD. Abstract 2354: An E2F signature predicts benefit of adjuvant chemotherapy in early-stage non-small cell lung cancer. Cancer Research. 73: 2354-2354. DOI: 10.1158/1538-7445.Am2013-2354 |
0.409 |
|
| 2012 |
Chen L, Chen DT, Kurtyka C, Rawal B, Fulp WJ, Haura EB, Cress WD. Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions. The Journal of Biological Chemistry. 287: 40106-18. PMID 23060449 DOI: 10.1074/Jbc.M112.380865 |
0.46 |
|
| 2011 |
Chen DT, Hsu YL, Fulp WJ, Coppola D, Haura EB, Yeatman TJ, Cress WD. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. Journal of the National Cancer Institute. 103: 1859-70. PMID 22157961 DOI: 10.1093/Jnci/Djr420 |
0.388 |
|
| 2011 |
Haviland R, Eschrich S, Bloom G, Ma Y, Minton S, Jove R, Cress WD. Necdin, a negative growth regulator, is a novel STAT3 target gene down-regulated in human cancer. Plos One. 6: e24923. PMID 22046235 DOI: 10.1371/Journal.Pone.0024923 |
0.683 |
|
| 2011 |
Kurtyka CA, Ma Y, Bian H, Cubitt C, Law B, Corsino P, Cress WD. Abstract 2943: Targeting the E2F pathway in cancer chemotherapeutics Cancer Research. 71: 2943-2943. DOI: 10.1158/1538-7445.Am2011-2943 |
0.502 |
|
| 2010 |
Brazelle W, Kreahling JM, Gemmer J, Ma Y, Cress WD, Haura E, Altiok S. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. Plos One. 5: e14335. PMID 21179472 DOI: 10.1371/Journal.Pone.0014335 |
0.484 |
|
| 2010 |
Sosa-García B, Gunduz V, Vázquez-Rivera V, Cress WD, Wright G, Bian H, Hinds PW, Santiago-Cardona PG. A role for the retinoblastoma protein as a regulator of mouse osteoblast cell adhesion: implications for osteogenesis and osteosarcoma formation. Plos One. 5: e13954. PMID 21085651 DOI: 10.1371/Journal.Pone.0013954 |
0.441 |
|
| 2010 |
Freeman SN, Cress WD. RhoBTB2 (DBC2) comes of age as a multifunctional tumor suppressor. Cancer Biology & Therapy. 10: 1123-5. PMID 20980811 DOI: 10.4161/Cbt.10.11.13786 |
0.382 |
|
| 2010 |
Ma Y, Chen L, Wright GM, Pillai SR, Chellappan SP, Cress WD. CDKN1C negatively regulates RNA polymerase II C-terminal domain phosphorylation in an E2F1-dependent manner. The Journal of Biological Chemistry. 285: 9813-22. PMID 20106982 DOI: 10.1074/Jbc.M109.091496 |
0.336 |
|
| 2009 |
Corsino P, Horenstein N, Ostrov D, Rowe T, Law M, Barrett A, Aslanidi G, Cress WD, Law B. A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism Journal of Biological Chemistry. 284: 29945-29955. PMID 19710018 DOI: 10.1074/Jbc.M109.055251 |
0.431 |
|
| 2008 |
He L, Yang H, Ma Y, Pledger WJ, Cress WD, Cheng JQ. Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression. The Journal of Biological Chemistry. 283: 31012-20. PMID 18776222 DOI: 10.1074/jbc.M803547200 |
0.384 |
|
| 2008 |
Ma Y, Kurtyka CA, Boyapalle S, Sung SS, Lawrence H, Guida W, Cress WD. A small-molecule E2F inhibitor blocks growth in a melanoma culture model. Cancer Research. 68: 6292-9. PMID 18676853 DOI: 10.1158/0008-5472.Can-08-0121 |
0.398 |
|
| 2008 |
Freeman SN, Ma Y, Cress WD. RhoBTB2 (DBC2) is a mitotic E2F1 target gene with a novel role in apoptosis. The Journal of Biological Chemistry. 283: 2353-62. PMID 18039672 DOI: 10.1074/Jbc.M705986200 |
0.458 |
|
| 2007 |
Wang C, Rauscher FJ, Cress WD, Chen J. Regulation of E2F1 function by the nuclear corepressor KAP1. The Journal of Biological Chemistry. 282: 29902-9. PMID 17704056 DOI: 10.1074/Jbc.M704757200 |
0.372 |
|
| 2006 |
Wang C, Chen L, Hou X, Li Z, Kabra N, Ma Y, Nemoto S, Finkel T, Gu W, Cress WD, Chen J. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nature Cell Biology. 8: 1025-31. PMID 16892051 DOI: 10.1038/Ncb1468 |
0.438 |
|
| 2006 |
Rodriguez JM, Glozak MA, Ma Y, Cress WD. Bok, Bcl-2-related Ovarian Killer, Is Cell Cycle-regulated and Sensitizes to Stress-induced Apoptosis. The Journal of Biological Chemistry. 281: 22729-35. PMID 16772296 DOI: 10.1074/Jbc.M604705200 |
0.448 |
|
| 2005 |
Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R, Briggs J, Karras J, Cress WD, Pardoll D, Jove R, Chen J, Yu H. Role of Stat3 in regulating p53 expression and function. Molecular and Cellular Biology. 25: 7432-40. PMID 16107692 DOI: 10.1128/Mcb.25.17.7432-7440.2005 |
0.464 |
|
| 2005 |
Song L, Coppola D, Livingston S, Cress WD, Haura EB. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biology & Therapy. 4: 267-276. PMID 15753661 DOI: 10.4161/Cbt.4.3.1496 |
0.483 |
|
| 2005 |
Wang C, Hou X, Mohapatra S, Ma Y, Cress WD, Pledger WJ, Chen J. Activation of p27Kip1 Expression by E2F1. A negative feedback mechanism. The Journal of Biological Chemistry. 280: 12339-43. PMID 15713665 DOI: 10.1074/Jbc.C400536200 |
0.475 |
|
| 2005 |
Bepler G, Zheng Z, Gautam A, Sharma S, Cantor A, Sharma A, Cress WD, Kim YC, Rosell R, McBride C, Robinson L, Sommers E, Haura E. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer (Amsterdam, Netherlands). 47: 183-92. PMID 15639717 DOI: 10.1016/J.Lungcan.2004.07.043 |
0.436 |
|
| 2004 |
Ma Y, Freeman SN, Cress WD. E2F4 deficiency promotes drug-induced apoptosis. Cancer Biology & Therapy. 3: 1262-9. PMID 15611646 DOI: 10.4161/Cbt.3.12.1239 |
0.363 |
|
| 2004 |
Haura EB, Cress WD, Chellappan S, Zheng Z, Bepler G. Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategies. Clinical Lung Cancer. 6: 113-22. PMID 15476597 DOI: 10.3816/Clc.2004.N.025 |
0.453 |
|
| 2004 |
Wang JW, Gamsby JJ, Highfill SL, Mora LB, Bloom GC, Yeatman TJ, Pan TC, Ramne AL, Chodosh LA, Cress WD, Chen J, Kerr WG. Deregulated expression of LRBA facilitates cancer cell growth. Oncogene. 23: 4089-97. PMID 15064745 DOI: 10.1038/Sj.Onc.1207567 |
0.512 |
|
| 2003 |
Ma Y, Yuan J, Huang M, Jove R, Cress WD. Regulation of the cyclin D3 promoter by E2F1. The Journal of Biological Chemistry. 278: 16770-6. PMID 12611887 DOI: 10.1074/Jbc.M212702200 |
0.391 |
|
| 2002 |
He Y, Cress WD. E2F-3B is a physiological target of cyclin A. The Journal of Biological Chemistry. 277: 23493-9. PMID 11980909 DOI: 10.1074/Jbc.M202629200 |
0.404 |
|
| 2002 |
Croxton R, Ma Y, Cress WD. Differences in DNA binding properties between E2F1 and E2F4 specify repression of the Mcl-1 promoter. Oncogene. 21: 1563-70. PMID 11896585 DOI: 10.1038/Sj.Onc.1205232 |
0.357 |
|
| 2002 |
Ma Y, Croxton R, Moorer RL, Cress WD. Identification of novel E2F1-regulated genes by microarray. Archives of Biochemistry and Biophysics. 399: 212-24. PMID 11888208 DOI: 10.1006/Abbi.2002.2761 |
0.42 |
|
| 2002 |
Croxton R, Ma Y, Song L, Haura EB, Cress WD. Direct repression of the Mcl-1 promoter by E2F1. Oncogene. 21: 1359-69. PMID 11857079 DOI: 10.1038/Sj.Onc.1205157 |
0.407 |
|
| 2002 |
Cress WD. Book Review: Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins.LaThangue NB, BandaraLR.Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins.Totowa, NJ: Humana Press, Inc; 2002. 352 pages. Casebound, $165.00 US Cancer Control. 9: 441-441. DOI: 10.1177/107327480200900512 |
0.389 |
|
| 2000 |
Hu X, Cress WD, Zhong Q, Zuckerman KS. Transforming growth factor beta inhibits the phosphorylation of pRB at multiple serine/threonine sites and differentially regulates the formation of pRB family-E2F complexes in human myeloid leukemia cells. Biochemical and Biophysical Research Communications. 276: 930-9. PMID 11027571 DOI: 10.1006/Bbrc.2000.3556 |
0.401 |
|
| 2000 |
Wharton W, Savell J, Cress WD, Seto E, Pledger WJ. Inhibition of mitogenesis in Balb/c-3T3 cells by Trichostatin A. Multiple alterations in the induction and activation of cyclin-cyclin-dependent kinase complexes. The Journal of Biological Chemistry. 275: 33981-7. PMID 10945992 DOI: 10.1074/Jbc.M005600200 |
0.413 |
|
| 2000 |
Zhang X, Wharton W, Donovan M, Coppola D, Croxton R, Cress WD, Pledger WJ. Density-dependent growth inhibition of fibroblasts ectopically expressing p27(kip1). Molecular Biology of the Cell. 11: 2117-30. PMID 10848633 DOI: 10.1091/Mbc.11.6.2117 |
0.37 |
|
| 2000 |
Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. Journal of Cellular Physiology. 184: 1-16. PMID 10825229 DOI: 10.1002/(Sici)1097-4652(200007)184:1<1::Aid-Jcp1>3.0.Co;2-7 |
0.314 |
|
| 1998 |
Dong F, Cress WD, Agrawal D, Pledger WJ. The role of cyclin D3-dependent kinase in the phosphorylation of p130 in mouse BALB/c 3T3 fibroblasts. The Journal of Biological Chemistry. 273: 6190-5. PMID 9497341 DOI: 10.1074/Jbc.273.11.6190 |
0.335 |
|
| 1997 |
Tao Y, Kassatly RF, Cress WD, Horowitz JM. Subunit composition determines E2F DNA-binding site specificity. Molecular and Cellular Biology. 17: 6994-7007. PMID 9372931 |
0.304 |
|
| 1994 |
Johnson DG, Cress WD, Jakoi L, Nevins JR. Oncogenic capacity of the E2F1 gene. Proceedings of the National Academy of Sciences of the United States of America. 91: 12823-7. PMID 7809128 DOI: 10.1073/Pnas.91.26.12823 |
0.324 |
|
| 1993 |
Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 365: 349-52. PMID 8377827 DOI: 10.1038/365349A0 |
0.359 |
|
| Show low-probability matches. |